TEMPISIN1234

CAMBRIDGE, Mass., Jan. 12, 2021 (GLOBE NEWSWIRE) — Cullinan Management, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, today announced the closing of its initial public offering of 13,685,000 shares of its common stock, including 1,785,000 shares sold pursuant to the full exercise of the underwriters’ option to purchase additional shares, at a price to the public of $21.00 per share. The gross proceeds of the offering were $287.4 million, before deducting underwriting discounts and commissions and other offering expenses. The shares began trading on the Nasdaq Global Select Market on January 8, 2021 under the symbol “CGEM.” All shares in the offering were offered by Cullinan Management. Published on : http://www.globenewswire.com/news-release/2021/01/13/2157564/0/en/Cullinan-Management-Announces-Closing-of-Initial-Public-Offering-and-Full-Exercise-of-Underwriters-Option-to-Purchase-Additional-Shares.html…

More

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Please note that the embedded hyperlinks in the press release below have been corrected from a release issued under the same headline earlier today. Published on : http://www.globenewswire.com/news-release/2021/01/08/2155319/0/en/Cullinan-Management-Announces-Pricing-of-Upsized-Initial-Public-Offering-CORRECTION.html…

More

CAMBRIDGE, Mass., Jan. 07, 2021 (GLOBE NEWSWIRE) — Cullinan Management, Inc., a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients, announced today the pricing of its upsized initial public offering of 11,900,000 shares of common stock at a price to the public of $21.00 per share. All shares are being offered by Cullinan Management. The gross proceeds to Cullinan Management from the offering, before deducting underwriting discounts, commissions and other offering expenses, are expected to be approximately $249.9 million. In addition, the underwriters have a 30-day option to purchase up to an additional 1,785,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. The shares are expected to begin trading on The Nasdaq Global Select Market under the ticker symbol “CGEM” on January 8, 2021. The offering is expected to close on January 12, 2021, subject to the satisfaction of customary closing conditions. Published on : http://www.globenewswire.com/news-release/2021/01/08/2155312/0/en/Cullinan-Management-Announces-Pricing-of-Upsized-Initial-Public-Offering.html…

More